Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the …
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the …
[HTML][HTML] Towards a population-based threshold of protection for COVID-19 vaccines
D Goldblatt, A Fiore-Gartland, M Johnson, A Hunt… - Vaccine, 2022 - Elsevier
Correlates of protection for COVID-19 vaccines are urgently needed to license additional
vaccines. We measured immune responses to four COVID-19 vaccines of proven efficacy …
vaccines. We measured immune responses to four COVID-19 vaccines of proven efficacy …
[HTML][HTML] Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …
[HTML][HTML] When to update COVID-19 vaccine composition
When to update COVID-19 vaccine composition | Nature Medicine Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …
you for visiting nature.com. You are using a browser version with limited support for CSS. To …
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
INTRODUCTION Mass vaccination against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) offers the most efficient public health intervention to control the COVID-19 …
(SARS-CoV-2) offers the most efficient public health intervention to control the COVID-19 …
[HTML][HTML] A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
L Chu, R McPhee, W Huang, H Bennett, R Pajon… - Vaccine, 2021 - Elsevier
Background Vaccines are urgently needed to prevent the global spread of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and …
respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and …
Differential antibody response to mRNA COVID-19 vaccines in healthy subjects
SE Wheeler, GV Shurin, M Yost, A Anderson… - Microbiology …, 2021 - Am Soc Microbiol
Knowledge about development and duration of virus-specific antibodies after COVID-19
vaccination is important for understanding how to limit the pandemic via vaccination in …
vaccination is important for understanding how to limit the pandemic via vaccination in …
[HTML][HTML] Evidence for antibody as a protective correlate for COVID-19 vaccines
A correlate of protection (CoP) is urgently needed to expedite development of additional
COVID-19 vaccines to meet unprecedented global demand. To assess whether antibody …
COVID-19 vaccines to meet unprecedented global demand. To assess whether antibody …
[HTML][HTML] Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers
Background Two doses of mRNA vaccination have shown> 94% efficacy at preventing
COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize …
COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize …